ArticlePediatric research2026
Bifidobacterium modulates gut microbiota and aryl hydrocarbon receptor signaling in necrotizing enterocolitis rat model.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The gut-brain axis in IgA vasculitis with neurological involvement: from association to experimentally tractable hypotheses.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal necrotizing enterocolitis (NEC) is linked to gut microbiota dysbiosis and inflammation. Bifidobacterium-mediated tryptophan metabolites, including indole-3-lactic acid (ILA), may exert anti-inflammatory effects via the aryl hydrocarbon receptor (AhR) pathway. This study investigated the protective effects and mechanisms of Bifidobacterium BB-12 in NEC.
methodsNeonatal rats were assigned to a control, NEC, and Bifidobacterium-treated NEC groups. Clinical symptoms, survival, serum cytokines, intestinal pathology, microbiota structure (16S rRNA sequencing), and AhR/CYP1A1 expression (quantitative reverse transcription polymerase chain reaction, western blotting) were evaluated. Colon metabolomics and in vitro lipopolysaccharide (LPS)-induced intestinal epithelial cell assays with AhR knockdown were performed to assess the role of ILA.
resultsBifidobacterium markedly alleviated symptoms, reduced intestinal damage, increased survival, and suppressed inflammatory factors. It restored gut microbiota diversity by increasing beneficial taxa (Bacteroidetes, Actinobacteria, Bifidobacterium), and decreasing pathogenic bacteria (Proteobacteria, Shigella-Escherichia). AhR/CYP1A1 expression was upregulated and negatively correlated with tissue damage. Metabolomics revealed elevated levels of ILA, indole-3-aldehyde, and 3-hydroxyanthranilic acid. In vitro, ILA inhibited LPS-induced inflammation and upregulated AhR/CYP1A1, while AhR knockdown largely abolished these effects.
conclusionBifidobacterium BB-12 protects against NEC by reshaping the gut microbiota, activating the AhR-CYP1A1 pathway, and regulating tryptophan metabolites, with ILA partially mediating its anti-inflammatory effects. IMPACT: Neonatal necrotizing enterocolitis is a severe inflammatory bowel disease in premature infants with limited treatment options, highlighting the need for new preventive and therapeutic strategies. Bifidobacterium is an effective probiotic, but its molecular mechanisms in NEC through host metabolic-immune interactions remain unclear. This study strongly suggest that in a neonatal rat NEC model, Bifidobacterium alleviates intestinal inflammation and tissue damage by reshaping the gut microbiota, elevating tryptophan metabolites like ILA, and activating the AhR-CYP1A1 signaling pathway. The findings provide a framework for understanding probiotic-mediated gut protection and potential targets for interventions using microbial metabolites or AhR agonists.
Identifiers
42668279What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.